MedPath

sefulness of Homoeopathy in the Treatment of urinary tract stones.

Phase 3
Conditions
Health Condition 1: N20-N23- Urolithiasis
Registration Number
CTRI/2023/08/056290
Lead Sponsor
none
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients diagnosed with urolithiasis (by radiological evidence: Ultrasonography of

lower abdomen/K.U.B/C.T/M.R.I etc.)

2.Patients between 20-70 years of age, all religions, all socio-economic status.

3.All sexes, genders, races.

4.Patients who are on lifesaving conventional drug therapies (e,g antidiabetics,

antihypertensives, thyroid drugs)to be continued uninterrupted.

6.Patients who are willing to give written consent to participate in the study.

Exclusion Criteria

1. Diagnosed cases of unstable mental or psychiatric illness.

2.Patients who are suffering from any life-threatening illness or other uncontrolled

systemic disease affecting quality of life or any other vital organ.

3.Patients who are suffering from any major complication, Congenital Anomalies of

Kidney and the Urinary Tract, severe hydronephrosis.

4.Patients who are on active treatment from any other system of medicine.

5.Patients not willing to give consent for participation in the study.

6.Patients not willing to undergo any investigation if advised.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome: Urolithiasis Symptom Score (USS score) <br/ ><br>On the basis of score obtained from USS index chart, cases according to intensity <br/ ><br>will be grouped into mild (1-7), moderate (8-14) and severe (15-22). The scores of the initial <br/ ><br>and follow ups will be compared.Timepoint: Baseline,3rd and 6th month of treatment
Secondary Outcome Measures
NameTimeMethod
ltrasonography of KUB region at baseline,3 <br/ ><br>rd and 6th month of treatment will be <br/ ><br>done to assess/compare the number, size and location of the calculus/calculi. <br/ ><br>Timepoint: Baseline,3rd and 6th month of treatment
© Copyright 2025. All Rights Reserved by MedPath